Proof of biology for amyloid plaque lowering therapies in pre‐clinical models of Alzheimer’s Disease

The current data therefore describe novel biomarker and functional insights into a key microglial pathway implicated in human disease and furthermore lay the framework for a translational biomarker strategy to support progression of Trem2 therapies for clinical development.

Authors

Choya Yoon

Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States) (US)

Publication Details

Journal: Alzheimer s & Dementia
Published: 2025-12-01
DOI: https://doi.org/10.1002/alz70859_100185
Primary Topic: Neuroinflammation and Neurodegeneration Mechanisms
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Proof of biology for amyloid plaque lowering therapies in pre‐clinical models of Alzheimer’s Disease

Choya Yoon

Dec 1, 2025

Alzheimer s & Dementia

Neuroinflammation and Neurodegeneration Mechanisms

article

Proof of biology for amyloid plaque lowering therapies in pre‐clinical models of Alzheimer’s Disease

Choya Yoon

December 1, 2025article en

Abstract

Alzheimer s & DementiaVol. 21(S5)

Merck & Co., Inc., Rahway, NJ, USA (United States) (US)

Openalex Percentile: Top 38%

Neuroinflammation and Neurodegeneration Mechanisms

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Proof of biology for amyloid plaque lowering therapies in pre‐clinical models of Alzheimer’s Disease — Choya Yoon · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS